Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Completes Acquisition of BioReliance for $403.2 Million

NEW YORK, Feb. 10 (GenomeWeb News) - Carlsbad, Calif.-based Invitrogen yesterday announced the closing of its acquisition of BioReliance in an all-cash deal conducted through its subsidiary entity, Baseball Acquisition.

BioReliance, a Rockville, Md.-based contract service organization, will operate as a wholly-owned subsidiary of Invitrogen. The firm in January announced that it would close a 44-employee Worchester, Mass., facility it acquired with a merger with Q-One Biotech in September.

BioReliance shares were delisted from the Nasdaq exchange, and ceased trading at the close of business on Friday, Feb. 6.

Invitrogen announced in December that it would acquire BioReliance for $500 million. Invitrogen paid $48 per share for BioReliance's approximately 8.4 million shares, valuing today's transaction at $403,200,000.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.